OUR PURPOSE PIONEERING SCIENCE 129 SASB CONTENT INDEX BIOGEN 2021 YEAR IN REVIEW PATIENTS OUR PEOPLE ENVIRONMENT COMMUNITY REPORTING Code Accounting Metric Biogen 2021 Response Affordability & Pricing HC-BP-240b.1. Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period Biogen does not comment on confidential legal matters. HC-BP-240b.2. Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year In 2021, we saw a list price increase of 3.805% and a net price decrease of 4.324% across our U.S. product portfolio compared to the previous year. In addition, Biogen’s anti-TNF biosimilars may have provided healthcare savings of approximately €2.6 billion in 2021 in the markets where they are sold. These savings may provide headroom for new innovative therapies to come to market. We regularly review our pricing strategy and prioritize patient access to our therapies. We have a value-based contracting program designed to align the price of our therapies to the value our therapies deliver to patients. We also work with regulators, clinical researchers, ethicists, physicians and Change to Patient Advocacy Groups and communities, among others, to determine how best to address requests for access to our investigational therapies in a manner that is consistent with our patient-focused values and compliant with regulatory standards and protocols. Additional information is available here: 2021 Annual Report Biogen Pricing Principles HC-BP-240b.3. Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year We regularly review our pricing strategy and prioritize patient access to our therapies. We have a value-based contracting program designed to align the price of our therapies to the value our therapies deliver to patients. We also work with regulators, clinical researchers, ethicists, physicians and Change to Patient Advocacy Groups and communities, among others, to determine how best to address requests for access to our investigational therapies in a manner that is consistent with our patient-focused values and compliant with regulatory standards and protocols. Additional information is available here: 2021 Annual Report Biogen Pricing Principles Drug Safety HC-BP-250a.1. List of products listed in the FDA’s MedWatch Safety Alerts for Human Medical Products database There were no listings relevant to Biogen’s products on the FDA’s MedWatch Safety Alerts for Human Medical Products database in 2021. HC-BP-250a.2. Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System All information related to fatalities associated with Biogen products is available via the FDA Adverse Event Reporting System . HC-BP-250a.3. Number of recalls issued, total units recalled A Class II VUMERITY recall that was initiated in December 2020 was closed in September 2021. For any relevant disclosures, please see Biogen’s 2021 Annual Report. HC-BP-250a.4. Total amount of product accepted for takeback, reuse, or disposal Biogen does not track the amount of product accepted for takeback, reuse or disposal; the volume of Biogen products is too low to warrant managing our own product takeback, reuse or disposal program. Biogen does, however, participate in several takeback programs across various U.S. states and counties, and several other countries. In addition, Biogen provides guidance on appropriate disposal methods for our products. HC-BP-250a.5. Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type Biogen did not receive any FDA enforcement actions associated with Form 483 observations, warning letters, seizures, recalls or consent decrees in 2021.